Dr. McFarlane is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8007 Discovery Dr
Ste A
Richmond, VA 23229Phone+1 804-287-3000Fax+1 804-673-2731
Education & Training
University of TennesseeFellowship, Hematology and Medical Oncology, 2006 - 2009
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 2003 - 2006
University of Texas Southwestern Medical SchoolClass of 2003
Certifications & Licensure
VA State Medical License 2003 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 17 citationsSafety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.Joshua J McFarlane, Mark D Kochenderfer, Mark R Olsen, Todd M Bauer, Ana Molina
Clinical Genitourinary Cancer. 2020-12-01 - 38 citationsA Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal CancerJohanna C. Bendell, Howard S. Hochster, Lowell L. Hart, Irfan Firdaus, Joseph R. Mace
The Oncologist. 2017-03-01 - 45 citationsSafety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.Nicholas J Vogelzang, Mark R Olsen, Joshua J McFarlane, Edward Arrowsmith, Todd M Bauer
Clinical Genitourinary Cancer. 2020-12-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
